⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

DUMMYHDLVR - Fundamental Analysis: Financial Health & Valuation

Back to List

Rating: 3.7

Last Updated Time : 04 May 26, 11:57 am

Fundamental Rating: 3.7

Stock Code DUMMYHDLVR Market Cap N/A Current Price N/A High / Low N/A
Stock P/E N/A Book Value N/A Dividend Yield N/A ROCE N/A
ROE N/A Face Value N/A DMA 50 N/A DMA 200 N/A
Chg in FII Hold N/A Chg in DII Hold N/A PAT Qtr N/A PAT Prev Qtr N/A
RSI N/A MACD N/A Volume N/A Avg Vol 1Wk N/A
Low price N/A High price N/A PEG Ratio N/A Debt to equity N/A
52w Index N/A Qtr Profit Var N/A EPS N/A Industry PE N/A

📊 Dr. Reddy’s Laboratories (DRREDDY) demonstrates strong fundamentals with ROE (20.3%) and ROCE (25.8%), supported by low debt-to-equity (0.13). EPS of ₹55.6 reflects robust earnings power, and dividend yield of 0.60% adds shareholder value. Valuation is fair with P/E (23.8) compared to industry average (30.1), while PEG ratio (0.49) suggests attractive growth-adjusted value. However, quarterly PAT dropped sharply (387 Cr → 90.6 Cr, -89.3%), raising concerns about earnings volatility. Technicals show bullish momentum with RSI (59.5), MACD (18.8), and price trading above both 50 DMA (1,267 ₹) and 200 DMA (1,257 ₹).

🎯 Entry Zone: 1,250 ₹ – 1,280 ₹ (near DMA support)

📌 Long-Term Holding: Suitable for accumulation with a 3–5 year horizon. Strong fundamentals justify holding, though short-term earnings volatility warrants cautious exposure. Upside potential exists toward 1,350–1,380 ₹ if profitability stabilizes.

Positive

  • Strong ROE (20.3%) and ROCE (25.8%) highlight efficiency.

  • Low debt-to-equity (0.13) ensures financial resilience.

  • EPS of ₹55.6 supports earnings visibility.

  • Valuation attractive with P/E (23.8) below industry average (30.1).

  • DII holdings increased (+0.28%), showing domestic institutional confidence.

Limitation

  • Quarterly PAT decline (-89.3%) highlights earnings weakness.

  • FII holdings decreased (-1.20%), showing reduced foreign investor confidence.

  • Dividend yield of 0.60% is modest compared to peers.

Company Negative News

  • Sharp quarterly profit decline raises concerns about short-term performance.

  • Reduced foreign institutional inflows (-1.20%).

Company Positive News

  • Strong efficiency metrics with high ROE and ROCE.

  • DII inflows (+0.28%) reflect domestic institutional support.

  • Valuation remains attractive relative to industry peers.

Industry

  • Industry P/E (30.1) is higher than DRREDDY’s 23.8, suggesting fair valuation.

  • Pharmaceutical sector remains resilient, supported by global demand for APIs and specialty formulations.

Conclusion

⚡ DRREDDY is fundamentally strong with efficient capital use and low debt. Entry around 1,250–1,280 ₹ offers favorable risk-reward. Long-term holding is justified with cautious accumulation, though short-term earnings volatility limits immediate upside. Partial profit booking near 1,350–1,380 ₹ is advisable, with exit below 1,240 ₹ on heavy volume.

This HTML report highlights Dr. Reddy’s strong fundamentals and fair valuation while flagging short-term earnings volatility. If you’d like, I can prepare a peer benchmarking overlay against Sun Pharma, Cipla, or Divi’s Labs to show relative positioning. Would you like me to build that next?

Back to List

NIFTY 50 - Fundamental Stock Watchlist

NEXT 50 - Fundamental Stock Watchlist

MIDCAP - Fundamental Stock Watchlist

SMALLCAP - Fundamental Stock Watchlist